MAPK8 and cancer: Low JNK signature was associated with worse overall survival compared to high JNK expression (p = 0.005), and patients with low JNK-expressing cancers had worse progression-free survival compared to patients with medium expression or high JNK pathway expression (low vs. med: p < 0.0001; low vs. high: p < 0.0001; Fig. 6C).